|
|
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Atenolol#Adult Indications and Dosage]] |
| | |
| ==List of indications==
| |
| <br>
| |
| <font size="4">[[Atenolol indications#Hypertension|Hypertension]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Atenolol indications#Angina pectoris|Angina Pectoris due to Coronary Atherosclerosis]]</font>
| |
| <br>
| |
| <br>
| |
| <font size="4">[[Atenolol indications#Hypertrophic Subaortic Stenosis|Hypertrophic Subaortic Stenosis]]</font>
| |
| <br>
| |
| <br>
| |
| -------
| |
| <br>
| |
| ===Hypertension===
| |
| | |
| Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
| |
| | |
| ''[[Atenolol indications#List of indications|Return to top]]''
| |
| <br>
| |
| | |
| ===Angina Pectoris Due to Coronary Atherosclerosis===
| |
| | |
| Atenolol tablets are indicated for the long-term management of patients with angina pectoris.
| |
| | |
| ''[[Atenolol indications#List of indications|Return to top]]''
| |
| <br>
| |
| | |
| ===Acute Myocardial Infarction===
| |
| | |
| Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows.
| |
| | |
| In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mmHg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mmHg) seemed less likely to benefit.
| |
| | |
| ''[[Atenolol indications#List of indications|Return to top]]''
| |
| <br>
| |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| [[Category:Drugs]]
| |